Amgen FY2025 EPS Forecast Increased by Cantor Fitzgerald

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Amgen in a research note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings per share of $20.90 for the year, up from their previous estimate of $20.85. Cantor Fitzgerald currently has a "Neutral" rating and a $305.00 target price on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. Cantor Fitzgerald also issued estimates for Amgen's FY2026 earnings at $21.47 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period last year, the business earned $3.96 earnings per share. The business's revenue was up 9.4% on a year-over-year basis.

AMGN has been the subject of a number of other reports. Royal Bank Of Canada decreased their price objective on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Piper Sandler restated an "overweight" rating and issued a $328.00 price objective on shares of Amgen in a report on Friday, June 27th. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Finally, Guggenheim assumed coverage on shares of Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus price target of $307.82.

Amgen Stock Down 1.7%

Shares of AMGN stock traded down $5.10 during trading hours on Thursday, hitting $295.27. 1,619,752 shares of the company's stock traded hands, compared to its average volume of 2,845,152. The stock's fifty day simple moving average is $283.56 and its two-hundred day simple moving average is $287.97. Amgen has a 12-month low of $253.30 and a 12-month high of $346.85. The stock has a market cap of $158.77 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 2.72 and a beta of 0.49. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70.

Institutional Investors Weigh In On Amgen

A number of hedge funds have recently modified their holdings of the business. Beck Mack & Oliver LLC raised its holdings in shares of Amgen by 0.7% in the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock valued at $1,205,000 after buying an additional 34 shares during the last quarter. Continuum Advisory LLC raised its holdings in shares of Amgen by 0.7% in the fourth quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock valued at $1,343,000 after buying an additional 35 shares during the last quarter. Octavia Wealth Advisors LLC raised its holdings in shares of Amgen by 1.5% in the first quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock valued at $759,000 after buying an additional 35 shares during the last quarter. Crumly & Associates Inc. raised its holdings in shares of Amgen by 3.2% in the second quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company's stock valued at $320,000 after buying an additional 36 shares during the last quarter. Finally, Trillium Asset Management LLC raised its holdings in shares of Amgen by 4.2% in the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock valued at $237,000 after buying an additional 37 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.76% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.